Screening and Detecting Counterfeit Biologics Drugs

Government health agencies and pharmaceutical manufacturers are finding ways to fight counterfeit and substandard drugs by identifying them from manufacturing, throughout the supply chain, and eventually when they reach the public after they are sold in the retail pharmacies. This whitepaper is co-authored by speaker Ravi Kalyanaraman of Bristol-Myers Squibb.

Please note: That all fields marked with an asterisk (*) are required.

Please Enter Your First Name
Please Enter Your Last Name
Please Enter Your Job Title
Please Enter Your Company Name
Please Enter Your Email Address
Please Enter Your Telephone
Please Select Your Country